The current study was aimed at formulating the ternary solid dispersion of docetaxel for treatment of breast cancer and evaluating its oral bioavailability
doi:10.1074/jbc.R113.458810
Thats whats changed. FDA-approved peptide drugs such as insulin and oxytocin have been available for decades
Key Findings Disparities in outcomes across different patient groups defined based on race, ethnicity, gender, age, socio-economic factors, and other factors are significant and can be attributed to many intersectional drivers related to healthcare awareness, access and delivery, in addition to factors related to genetics While access and delivery of care are major factors driving disparities in outcomes, a comprehensive clinical development program that addresses diversity and ranges from pre-clinical and exploratory studies through randomized confirmatory trials for safety and efficacy through to post-approval real-world studies can advance understanding of optimal patient care, expand access to care, bring earlier insights, and accelerate innovation Stakeholders in the U.S
Compared with conventional synthetic drugs, these biologic agents offer multiple advantages
Side Effects & Safety No lethal dose found -- toxicology studies couldn't establish an LD50 (Sikiric et al., 2006) No organ toxicity in chronic dosing No hormonal effects -- doesn't affect testosterone, estrogen, cortisol, or GH Mild nausea -- mostly with oral dosing Brief lightheadedness -- occasionally after injection Injection site redness -- standard for SC peptides Angiogenesis concern -- promotes new blood vessel growth, which raises a theoretical question about existing tumors
